The ESA

CMDh decision on HES solutions

09 Jul 2018

The ESA is happy to announce that the CMDh (Coordination group For Mutual recognition and Decentralised Procedures – humans, part of the European Medical Agency) in its meeting on June 25th, concluded that Hydroxyethyl Starch (HES) solutions for infusions should remain on the market. See the decision on the EMA website.

ESA will contribute to the combination of new risk minimisation measures requested by CMDh to ensure that HES solutions are not used in patients at risks. In particular, ESA will be involved in training healthcare professionals in the safe use of HES products. 

In parallel, ESA continues acting as an Academic Contract Research Organisation to assess the safety and efficacy of HES solutions: PHOENICS and TETHYS trials